Pharmaceutical Stocks that must be added to your Investment Portfolio
Pharmaceuticals are the fastest growing sector of the economy, and this is your chance to make a lot of money. Your investment will grow exponentially, and you'll be able to retire early with all the cash you need. Of course, it's not too late for you to get into pharmaceutical stocks - with a little luck and a lot of savvy decisions on which drug company to buy shares in, you could start seeing huge returns within months!
If this sounds like an opportunity too good to pass up, then why not turn your attention toward pharmaceutical stocks? It's only going to get bigger from here.
Which Pharmaceutical Stocks are best?
There are a variety of companies that are involved in pharmaceutical research, production, and distribution. They require different strategies to invest in. Some of the most notable in the market are Johnson & Johnson (NYSE: JNJ), Pfizer (NYSE: PFE), Merck & Co. (NYSE: MRK), and Bristol-Myers Squibb (NYSE: BMY). By looking at these companies, you can determine which drug stocks to invest in or whether it's time to look for some other opportunities.
JNJ- Johnson & Johnson
- Stock price: JNJ (NYSE) US$176.15
- Market Cap: 463 Billion
Johnson & Johnson is the world's largest health care company. It is also the highest-paid drug company in the world. J&J remains at the top of the Big Pharma list of powerful corporations with more than $82 billion in annual revenue in 2020. Its top products include Tylenol, Stelara, Invega, and various medical devices. Shares of J&J have an Investor's Business Daily Composite Rating of 89 out of a best-possible 99. The CR scores a stock's key growth metrics against all other stocks regardless of the industry group. So in terms of key growth measures, JNJ stock outranks 89% of all stocks.
GILD- Gilead Sciences, Inc.
- Stock price: GILD (NASDAQ) US$62.18
- Revenue: 24.69 billion USD (2020)
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, and influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. The 22 analysts offering 12-month price forecasts for Gilead Sciences Inc have a median target of 68.50, with a high estimate of 90.00 and a low estimate of 56.00. The median estimate represents a +10.43% increase from the last price of 62.03.
CYTH- Cyclo Therapeutics Inc.
- Stock price: CYTH (NASDAQ) US$2.17
- Revenue: 194.9K (March 2022)
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases. Based on analyst ratings, Cyclo Therapeutics's 12-month average price target is $10.00. What is CYTH's upside potential, based on the analysts' average price target? Cyclo Therapeutics has 352.49% upside potential, based on the analysts' average price target.
RDY- Dr. Reddy's Laboratories Ltd
- Stock price: DRREDDY (NSE) ₹4,324.95
- Revenue: 174.6 billion INR (US$2.3 billion, 2020)
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. The financial health and growth prospects of RDY demonstrate its potential to outperform the market. It currently has a Growth Score of A. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D.